Browsing publications by Huw Thomas

Newcastle AuthorsTitleYear
Dr Frida Ponthan
Claire Whitworth
Huw Thomas
Dr Christopher Redfern
Cell Survival Signalling through PPAR╬┤ and Arachidonic Acid Metabolites in Neuroblastoma2013
Christopher Hill
Dr David Jamieson
Huw Thomas
Dr Colin Brown
Professor Alan Boddy
et al.
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo2013
Emma Haagensen
Huw Thomas
Ian Wilson
Dr Suzannah Harnor
Dr Sara Henderson
et al.
The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice2013
Dr Anastasia Hepburn
Dr Stuart Williamson
Dr Amira El-Sherif
Dr Neha Sahay
Huw Thomas
et al.
Side Population in Human Non-Muscle Invasive Bladder Cancer Enriches for Cancer Stem Cells That Are Maintained by MAPK Signalling2012
Dr Emma Meczes
Huw Thomas
Professor Richard Edmondson
Dr Gareth Veal
Professor Alan Boddy
et al.
Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours2012
Huw Thomas
Professor Herbie Newell
Professor Nicola Curtin
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition2011
Dr Kappusamy Saravanan
Hannah Barlow
Marion Barton
Professor Hilary Calvert
Professor Bernard Golding
et al.
Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of ╬▒1-Acid Glycoprotein2011
Tomasz Zaremba
Huw Thomas
Mike Cole
Dr Sally Coulthard
Professor Ruth Plummer
et al.
Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers2011
Huw Thomas
Dr Celine Roche
Dr Johanne Bentley
Dr Ian Hardcastle
Professor Bernard Golding
et al.
Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU63012011
Huw Thomas
Suzanne Kyle
Ivanda Pavlovska
Professor Nicola Curtin
The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice2011
123456